ASCO 2024: Key Findings of the LAURA Trial on Osimertinib for EGFR-Mutated NSCLC

Key Takeaways

• Osimertinib significantly improved progression-free survival in unresectable stage III EGFR-mutated NSCLC post-definitive CRT, as shown in the phase 3 LAURA trial.
• The trial results suggest osimertinib may become a new standard of care for patients with EGFR-mutated NSCLC, enhancing treatment strategies.
• Targeted therapies like osimertinib highlight the evolving landscape of NSCLC management, emphasizing personalized treatment approaches for better patient outcomes.